Summit Therapeutics Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $10.67
- 52-Week Range
- $10.14 – $29.23
- Market Cap
- $8.40B
- P/E (TTM)
- —
- EPS (TTM)
- -1.06
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 14.87
- PEG Ratio
- —
- Return on Equity
- -220.01%
- Return on Assets
- -111.99%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 5.99
- Debt/Equity
- 0.04
- Total Debt
- $19.98M
- Free Cash Flow
- $-213.92M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $7.79B
Market Snapshot
About
Summit Therapeutics Inc. is a biopharmaceutical company focused on developing innovative antibiotics and precision medicines for serious infectious diseases and oncology. The company is advancing ivonescimab, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. Summit is conducting global clinical trials to address antibiotic-resistant infections and difficult-to-treat cancers.